Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US11052093 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Apr, 2032
(7 years from now) | |
US9090562 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Apr, 2032
(7 years from now) | |
US10821113 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(8 years from now) | |
US9394283 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(8 years from now) | |
US8410088 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Jan, 2034
(9 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9949999 | EPIZYME INC | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(7 years from now) | |
US9334527 | EPIZYME INC | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(7 years from now) | |
US8895245 | EPIZYME INC | Inhibitors of human EZH2 and methods of use thereof |
Sep, 2031
(7 years from now) | |
US9175331 | EPIZYME INC | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(7 years from now) | |
US8691507 | EPIZYME INC | Inhibitors of human EZH2 and methods of use thereof |
Sep, 2031
(7 years from now) | |
US9333217 | EPIZYME INC | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(7 years from now) | |
US8765732 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Apr, 2032
(7 years from now) | |
US9855275 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Apr, 2032
(7 years from now) | |
US10155002 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Apr, 2032
(7 years from now) | |
US9522152 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Apr, 2032
(7 years from now) | |
US9549931 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Apr, 2032
(7 years from now) | |
US10420775 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Apr, 2032
(7 years from now) | |
US10245269 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(8 years from now) | |
US11491163 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(8 years from now) | |
US9872862 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(8 years from now) | |
US9688665 | EPIZYME INC | Methods of treating cancer |
Aug, 2034
(10 years from now) | |
US9889138 | EPIZYME INC | Method for treating cancer |
Oct, 2035
(11 years from now) | |
US10369155 | EPIZYME INC | Method for treating cancer |
Oct, 2035
(11 years from now) | |
US10786511 | EPIZYME INC | Method for treating cancer |
Dec, 2035
(11 years from now) |
Tazverik is owned by Epizyme Inc.
Tazverik contains Tazemetostat Hydrobromide.
Tazverik has a total of 24 drug patents out of which 0 drug patents have expired.
Tazverik was authorised for market use on 23 January, 2020.
Tazverik is available in tablet;oral dosage forms.
Tazverik can be used as method of treating a lung metastasis of epithelioid sarcoma, method of treating epithelioid sarcoma, method of treating sarcoma, method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation by inhibiting ezh2, method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation, method of treating relapsed or refractory follicular lymphoma, method of treating relapsed or refractory follicular lymphoma by inhibiting ezh2.
Drug patent challenges can be filed against Tazverik from 24 January, 2024.
The generics of Tazverik are possible to be released after 19 December, 2035.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jan 23, 2025 |
Orphan Drug Exclusivity(ODE-314) | Jun 18, 2027 |
Orphan Drug Exclusivity(ODE-299) | Jan 23, 2027 |
New Indication(I-835) | Jun 18, 2023 |
New Indication(I-836) | Jun 18, 2023 |
Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient
NCE-1 date: 24 January, 2024
Market Authorisation Date: 23 January, 2020
Treatment: Method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation by inhibiting ezh2; Method of treating relapsed or refractory follicular lymph...
Dosage: TABLET;ORAL